Patents by Inventor Joaquim Bellmunt

Joaquim Bellmunt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR CHARACTERIZING BLADDER CANCER
    Publication number: 20240229148
    Abstract: The present invention features methods for characterizing mutational profiles in patients with bladder cancer.
    Type: Application
    Filed: November 13, 2023
    Publication date: July 11, 2024
    Applicants: The Broad Institute, Inc., The General Hospital Corporation, Baylor College of Medicine, The Brigham and Women's Hospital, Inc., Northwestern University, The Johns Hopkins University, United States Government as represented by the U.S. Department of Veterans Affairs
    Inventors: Jaegil KIM, Gad GETZ, Seth Paul LERNER, David KWIATKOWSKI, Joshua MEEKS, Joaquim BELLMUNT, David MCCONKEY
  • Methods for characterizing bladder cancer
    Patent number: 11814687
    Abstract: The present invention features methods for characterizing mutational profiles in patients with bladder cancer.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: November 14, 2023
    Assignees: The Broad Institute, Inc., The General Hospital Corporation, Baylor College of Medicine, The Brigham and Women's Hospital, Inc., Northwestern University, The Johns Hopkins University, United States Government as represented by the U.S. Department of Veterans Affairs
    Inventors: Jaegil Kim, Gad Getz, Seth Paul Lerner, David Kwiatkowski, Joshua Meeks, Joaquim Bellmunt, David McConkey
  • COMPOSITIONS AND METHODS FOR CHARACTERIZING BLADDER CANCER
    Publication number: 20200370133
    Abstract: The present invention features methods for characterizing mutational profiles in patients with bladder cancer.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 26, 2020
    Applicants: The Broad Institute, Inc., The General Hospital Corporation, Baylor College of Medicine, The Brigham and Women?s Hospital, Inc., Northwestern University, The Johns Hopkins University, United States Government as represented by the U.S. Department of Veterans Affairs
    Inventors: Jaegil Kim, Gad Getz, Seth Paul Lerner, David Kwiatkowski, Joshua Meeks, Joaquim Bellmunt, David McConkey
  • CHROMOSOME COPY NUMBER GAIN AS A BIOMARKER OF UROTHELIAL CARCINOMA LETHALITY
    Publication number: 20180135132
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Application
    Filed: October 24, 2017
    Publication date: May 17, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda
  • Chromosome copy number gain as a biomarker of urothelial carcinoma lethality
    Patent number: 9828643
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: November 28, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda
  • CHROMOSOME COPY NUMBER GAIN AS A BIOMARKER OF UROTHELIAL CARCINOMA LETHALITY
    Publication number: 20130165331
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Application
    Filed: May 18, 2012
    Publication date: June 27, 2013
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda
  • CHROMOSOME COPY NUMBER GAIN AS A BIOMARKER OF UROTHELIAL CARCINOMA LETHALITY
    Publication number: 20120295807
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Application
    Filed: May 18, 2012
    Publication date: November 22, 2012
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda